 |
|
Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in WomenThe Women's Antioxidant and Folic Acid Cardiovascular Study
William G. Christen, ScD;
Robert J. Glynn, ScD;
Emily Y. Chew, MD;
Christine M. Albert, MD;
JoAnn E. Manson, MD
Arch Intern Med. 2009;169(4):335-341.
Background Observational epidemiologic studies indicate a direct association between homocysteine concentration in the blood and the risk of age-related macular degeneration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are lacking. Our objective was to examine the incidence of AMD in a trial of combined folic acid, pyridoxine hydrochloride (vitamin B6), and cyanocobalamin (vitamin B12) therapy.
Methods We conducted a randomized, double-blind, placebo-controlled trial including 5442 female health care professionals 40 years or older with preexisting cardiovascular disease or 3 or more cardiovascular disease risk factors. A total of 5205 of these women did not have a diagnosis of AMD at baseline and were included in this analysis. Participants were randomly assigned to receive a combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d) or placebo. Our main outcome measures included total AMD, defined as a self-report documented by medical record evidence of an initial diagnosis after randomization, and visually significant AMD, defined as confirmed incident AMD with visual acuity of 20/30 or worse attributable to this condition.
Results After an average of 7.3 years of treatment and follow-up, there were 55 cases of AMD in the combination treatment group and 82 in the placebo group (relative risk, 0.66; 95% confidence interval, 0.47-0.93 [P = .02]). For visually significant AMD, there were 26 cases in the combination treatment group and 44 in the placebo group (relative risk, 0.59; 95% confidence interval, 0.36-0.95 [P = .03]).
Conclusions These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.
Trial Registration clinicaltrials.gov Identifier NCT00000161
Author Affiliations: Divisions of Preventive Medicine (Drs Christen, Glynn, Albert, and Manson) and Cardiovascular Medicine (Dr Albert), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and Departments of Biostatistics (Dr Glynn) and Epidemiology (Dr Manson), Harvard School of Public Health, Boston, Massachusetts; and National Eye Institute, Bethesda, Maryland (Dr Chew).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Beyond AREDS: Is There a Place for Antioxidant Therapy in the Prevention/Treatment of Eye Disease?
Kowluru and Zhong
IOVS 2011;52:8665-8671.
ABSTRACT
| FULL TEXT
Healthy Lifestyles Related to Subsequent Prevalence of Age-Related Macular Degeneration
Mares et al.
Arch Ophthalmol 2011;129:470-480.
ABSTRACT
| FULL TEXT
The Role of Micronutrients in Managing Diabetes
Chehade et al.
Diabetes Spectr. 2009;22:214-218.
ABSTRACT
| FULL TEXT
Plasma Protein Pentosidine and Carboxymethyllysine, Biomarkers for Age-related Macular Degeneration
Ni et al.
Mol. Cell. Proteomics 2009;8:1921-1933.
ABSTRACT
| FULL TEXT
Multivitamin Supplements, Ageing, and Loss of Vision: Seeing Through the Shadows
Phillips and Higginbotham
Arch Intern Med 2009;169:1180-1182.
FULL TEXT
B Vitamin Supplementation and Age-Related Macular Degeneration
JWatch General 2009;2009:3-3.
FULL TEXT
Vitamins Might Help Prevent Blindness
JWatch Women's Health 2009;2009:3-3.
FULL TEXT
All you need to read in the other general journals
BMJ 2009;338:b863-b863.
FULL TEXT
|
